Group 1 - The A-share medical sector showed positive performance on February 27, with the largest medical ETF (512170) rising by 1.14% and successfully recovering the annual line, with a transaction volume of 384 million CNY [1][9] - The ETF experienced continuous premium trading, indicating a positive buying sentiment, with over 190 million CNY net subscriptions in the previous three days [1][9] - The leading stock, Huatai Medical, surged by 8.24%, with its performance report indicating over 20% year-on-year growth in revenue and net profit for 2025 [1][11] Group 2 - The Hong Kong medical sector rebounded after several days of decline, with the Hong Kong medical ETF (159137) recovering from a historical low, ending a six-day losing streak [3][11] - CXO companies, particularly those under WuXi AppTec, showed strong performance, with shares rising by 8.23% for WuXi AppTec, 5% for WuXi Biologics, and 3.21% for WuXi AppTec [3][11] - Citic Securities remains optimistic about the growth potential and space for the CXO sector due to increasing overseas orders and a gradual recovery in domestic demand [4][12] Group 3 - In the medical device industry, Citic Securities believes that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, suggesting an allocation increase in 2026 [6][14] - Investment opportunities are expected to arise from performance recovery, international expansion, brain-computer interfaces, and AI medical applications [6][14] - The medical ETF fund size reached 27.7 billion CNY, making it the largest in the medical sector, covering various themes including brain-computer interfaces and innovative medical devices [7][14]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

Core Viewpoint - The company has successfully completed the stock purchase under its 2026 employee stock ownership plan, acquiring a total of 1,018,847 shares, which represents 0.48% of the company's total share capital, with a transaction amount of 98.0693 million yuan [1]. Group 1 - The company held its 24th meeting of the 3rd Board of Directors on January 23, 2026, where it approved the employee stock ownership plan and its management measures [1]. - The stock purchased will be locked for 12 months from the date of this announcement, and upon meeting relevant assessment conditions, the rights will be unlocked and distributed to the holders [1].

Core Viewpoint - The company, Yirui Technology (688301.SH), has completed the stock purchase under its 2026 employee stock ownership plan, acquiring a total of 1,018,847 shares, which represents 0.48% of the company's total share capital, with a transaction amount of 98.0693 million yuan [1] Group 1 - The employee stock ownership plan has been executed as per the draft regulations, with the shares purchased locked for 12 months from the announcement date [1] - After the lock-up period, the shares will be unlocked and distributed to holders, contingent upon meeting specific assessment criteria [1]

Core Viewpoint - The company, Yirui Technology (688301.SH), has completed the stock purchase under its 2026 employee stock ownership plan, acquiring a total of 1,018,847 shares, which represents 0.48% of the company's total share capital, with a transaction amount of 98.0693 million yuan [1] Group 1 - The employee stock ownership plan has been executed as per the draft regulations, with a total of 1,018,847 shares purchased [1] - The total transaction amount for the stock purchase is 98.0693 million yuan, excluding commissions and transfer fees [1] - The acquired shares will be locked for 12 months from the date of the announcement, with conditions for unlocking and distribution of rights to the holders after the lock-up period [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-012 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于 2026 年员工持股计划完成股票购买的公告 特此公告。 奕瑞电子科技集团股份有限公司董事会 2026年2月27日 奕瑞电子科技集团股份有限公司（以下简称"公司"）于2026年1月23日召开第 三届董事会第二十四次会议审议通过了《关于<公司2026年员工持股计划（草案） >及其摘要的议案》《关于<公司2026年员工持股计划管理办法>的议案》等相关 议 案 ， 具 体 内 容 详 见 公 司 于 2026 年 1 月 24 日 在 上 海 证 券 交 易 所 网 站 （ www.sse.com.cn）披露的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易所 科创板上市公司自律监管指引第1号——规范运作》等相关法规要求，现将公司 2026年员工持股计划实施进展情况公告如下： 截至本公告披露日，公司2026年员工持股计划已完成标的股票的购买，通过 《2026 年员工持 ...

Group 1 - The core transaction involved 498,800 shares of Yirui Technology, with a total transaction value of 47.8893 million yuan, accounting for 13.85% of the total trading volume on that day [1][2] - The transaction price was 96 yuan per share, representing a discount of 20.59% compared to the market closing price of 120.89 yuan [1]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-011 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 二、审议通过《关于选举公司 2026 年员工持股计划管理委员会委员的议案》。 经审议表决，选举朱建秋、卞韧、胡顺金为公司 2026 年员工持股计划管理 委员会委员，管理委员会委员任期与公司 2026 年员工持股计划的存续期一致。 公司已于同日召开 2026 年员工持股计划管理委员会第一次会议，选举朱建 秋为管理委员会主任，任期自当选之日起至本持股计划终止之日止。 奕瑞电子科技集团股份有限公司 2026 年员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）2026 年员工持股计划 第一次持有人会议（以下简称"本次会议"）于 2026 年 2 月 9 日以现场结合通讯 方式在公司会议室召开。本次会议由公司董事会秘书卞韧先生召集并主持。会议 的召集和召开程序符合 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （一）股东会召开的时间：2026年2月9日 （二）股东会召开的地点：上海市浦东新区环桥路999号奕瑞电子科技集团股份有限公司一楼会议室 （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、本次股东会所采用的表决方式是现场投票和网络投票相结合的方式。 2、召集与主持情况：本次会议由公司董事会召集，董事长Tieer Gu先生因公务未能现场出席本次会 议，选择远程线上接入，经董事会过半数董事共同推举，会议由公司董事Chengbin Qiu先生主持。 本次会议的召集和召开程序以及表决方式和表决程序均符合《公司法》及《公司章程》的规定，会议合 法有效。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席9人； 2、董事会秘书卞韧先生出席本次会议；其他高级管理人员列席本次会议。 二、 ...